Related Experiment Video
Updated: Jun 7, 2025
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
Identification and validation of miR-21 key genes in cervical cancer through an integrated bioinformatics approach
Tandrima Mitra1, Monica Prusty1, Selvakumar Elangovan1
1School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT), Deemed to be University, Bhubaneswar, Odisha 751024, India.
Abstract:
Cervical cancer is one of the most prevalent female reproductive cancers. miR-21 is a multi-target oncomiR that has shown its potential in regulating several cancers including colon, pancreatic, breast, prostate, ovarian, and cervical cancer. However, the signaling network of miR-21 remains underexplored, and only a limited number of miR-21 gene targets in cervical cancer have been reported. In this context, the present study was undertaken to evaluate the role of miR-21 in cervical cancer by combining in silico analysis with in vitro validation in cervical cancer cells. The miR-21 target genes were predicted using four different prediction tools: miRWalk, DIANA, miRDB, and TargetScan. A total of 113 overlapping target genes, common in at least three of the prediction tools, were shortlisted and subjected to functional enrichment analysis. The analysis predicted that JAK-STAT, MAPK, neurotrophin, and Ras signaling pathways are significantly (p≤0.05) targeted by miR-21. The MCODE plugin identified the potential cluster in the protein-protein interaction network based on the highest degree of connectivity. After GEPIA2 validation of all 20 hub genes, NTF3, LIFR, and IL-6R were shortlisted for validation in cervical cancer cell lines. The results showed that NTF3, LIFR, and IL-6R were significantly upregulated in the miR-21 knockdown CaSki cell lines in 6.27, 1.92 and 1.71 folds (p≤0.01), respectively. Similarly, in HeLa cell lines expression of NTF3, LIFR, and IL-6R were overexpressed in 4.06, 5.65, 2.42 folds (p≤0.001), respectively. Findings of the study was confirming the role of miR-21 in regulating the expression of these genes. Additionally, the knockdown of miR-21 significantly inhibited the secretion of matrix metalloproteinases by CaSki cells. These results highlight that miR-21 could be a potential therapeutic target for cervical cancer, although further preclinical and clinical studies are required to validate its role and efficacy.
Insights
MicroRNA-21 (miR-21) plays a key role in cervical cancer by regulating genes like NTF3, LIFR, and IL-6R. Inhibiting miR-21 shows therapeutic potential by reducing cancer cell growth and matrix metalloproteinase secretion.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- Cervical cancer is a prevalent female reproductive cancer.
- MicroRNA-21 (miR-21) is an oncomiR implicated in various cancers, but its network in cervical cancer is underexplored.
- Limited miR-21 gene targets have been identified in cervical cancer.
Purpose of the Study:
- To evaluate the role of miR-21 in cervical cancer.
- To identify and validate miR-21 gene targets in cervical cancer cells.
- To explore miR-21's potential as a therapeutic target.
Main Methods:
- In silico prediction of miR-21 target genes using miRWalk, DIANA, miRDB, and TargetScan.
- Functional enrichment and protein-protein interaction network analysis of overlapping target genes.
- In vitro validation of selected targets (NTF3, LIFR, IL-6R) in cervical cancer cell lines (CaSki and HeLa) with miR-21 knockdown.
- Assessment of matrix metalloproteinase secretion after miR-21 knockdown.
Main Results:
- 113 overlapping miR-21 target genes were identified, implicating JAK-STAT, MAPK, neurotrophin, and Ras signaling pathways.
- NTF3, LIFR, and IL-6R were significantly upregulated in miR-21 knockdown cervical cancer cell lines.
- miR-21 knockdown inhibited matrix metalloproteinase secretion in CaSki cells.
Conclusions:
- miR-21 significantly regulates the expression of NTF3, LIFR, and IL-6R in cervical cancer.
- miR-21 inhibition demonstrates potential therapeutic efficacy by impacting cancer cell behavior.
- Further preclinical and clinical studies are warranted to validate miR-21 as a therapeutic target for cervical cancer.
